Can mild glycemic strain raise hepatic VLDL, triglycerides, and apoB-containing particle burden even when fasting insulin is normal?

Early metabolic dysregulation often alters lipid metabolism long before classic clinical markers indicate overt cardiovascular or metabolic disease.

Mechanistic pathways of glycemic strain

• Postprandial glucose elevations act as a direct hepatic stimulus, activating the glucose-responsive transcription factor Carbohydrate Response Element-Binding Protein (ChREBP).
• ChREBP upregulates the expression of microsomal triglyceride transfer protein (MTTP), accelerating the assembly, packaging, and secretion of triglyceride-rich very-low-density lipoproteins (VLDL).

Downstream remodeling and particle burden

• Enhanced VLDL synthesis and secretion directly raise circulating triglyceride levels.
• These triglyceride-rich lipoproteins undergo rapid intravascular lipolysis and enzymatic remodeling, yielding highly atherogenic remnant lipoproteins and increasing the total circulating concentration of apolipoprotein B (apoB) and low-density lipoprotein particles (LDL-P).

Clinical implications

• This atherogenic cascade remains highly active even in individuals with clinically normal fasting insulin levels.
• Fasting insulin is an insensitive marker for early-stage, tissue-specific insulin resistance and transient postprandial glycemic strain, both of which are sufficient to impair the normal insulin-mediated suppression of hepatic VLDL secretion.

Bottom line

• Mild glycemic strain directly drives hepatic VLDL secretion and downstream apoB/remnant particle burden via ChREBP-MTTP activation, representing a significant cardiovascular risk pathway that fasting insulin measurements routinely miss.